Titles and Legends for Supplementary Figures
Supplementary Figure S1 . Gating strategy for activation markers on (a) CD4+ and (b) CD8+ T cells. Expression of T cell activation markers was assessed by flow cytometry. Gates for positive events were set using fluorescence minus one (FMO) controls. For the gating strategy to identify CD4+ and CD8+ T cells, see Supplementary Fig S9. Supplementary Figure S2 . Expression of activation markers on Ingenol-db-or mitogen-stimulated T cells. Expression of activation markers on CD4+ and CD8+ T cells exposed to Ingenol-db or PHA/IL-2. PBMC from HIV-seropositive participants durably suppressed on cART (n=7) were exposed to vehicle (0.5% DMSO), Ingenol-db, or PHA/IL-2 for 3, 6, 12, or 24 hours, washed to remove extracellular drug, and maintained in vehicle for the remainder of the culture period. Activation marker expression was assessed at 24 hours. MFI, mean fluorescence intensity. Measurements were compared between vehicle and Ingenol-db or PHA/IL-2 treatment using an exact Wilcoxon Signed Rank test. * p < 0.05; ** p ≤ 0.016. Figure S3 . Expression of activation markers on memory T cells exposed to HDACis. PBMC from HIV-seropositive participants durably suppressed on cART (n=7) were exposed to vehicle (0.5% DMSO) or HDACis for 3, 6, 12, or 24 hours, washed to remove extracellular drug, and maintained in vehicle for the remainder of the culture period. Activation and memory marker expression was measured at 24 hours. (A) Expression of the T cell memory marker CD45RO on CD4+ and CD8+ T cells. (B) Expression of activation markers on memory (CD45RO+) CD4+ and CD8+ T cells. MFI, mean fluorescence intensity. Measurements were compared between vehicle and HDACi treatment using an exact Wilcoxon Signed Rank test. * p < 0.05; ** p ≤ 0.016.
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Supplementary Figure S4. Expression of activation markers on T cells exposed to HDACis or PKCms.
PBMC from HIV-seronegative participants (n=7) were exposed to vehicle (0.5% DMSO) or LRA for 3 hours, washed to remove extracellular drug, and maintained in vehicle for the remainder of the culture period. Activation marker expression was measured at 24, 48, and 72 hours. MFI, mean fluorescence intensity. Figure S5 . Expression of activation markers over 72 hours on mitogen-stimulated T cells. Expression of activation markers on CD4+ and CD8+ T cells exposed to the positive control PHA/IL-2. PBMC from HIV-seropositive participants durably suppressed on cART (n=8) were exposed to vehicle (0.5% DMSO) or PHA/IL-2 for 3 hours, washed to remove extracellular drug, and maintained in vehicle for 72 hours. Activation marker expression was assessed at 24, 48, and 72 hours. Measurements were compared between vehicle and PHA/IL-2 treatment using an exact Wilcoxon Signed Rank test. * p < 0.05; ** p ≤ 0.016. Figure S6 . Expression of activation markers on memory T cells exposed to HDACis or PKCms. PBMC from HIV-seropositive participants durably suppressed on cART (n=7) were exposed to vehicle (0.5% DMSO) or LRA for 3 hours, washed to remove extracellular drug, and maintained in vehicle for the remainder of the culture period. Activation and memory marker expression was measured at 24, 48, and 72 hours. (a) Expression of the T cell memory marker CD45RO on CD4+ and CD8+ T cells. (b) Expression of activation markers on memory (CD45RO+) CD4+ and CD8+ T cells. MFI, mean fluorescence intensity. Measurements were compared between vehicle and LRA treatment using an exact Wilcoxon Signed Rank test. * p < 0.05; ** p ≤ 0.016. Figure S7 . Expression of activation markers on T cells exposed to HDACis or PKCms for 6 hours. PBMC from HIV-seropositive participants durably suppressed on cART (n=8) were exposed to vehicle (0.5% DMSO) or LRA for 6 hours, washed to remove extracellular drug, and maintained in vehicle for the remainder of the culture period. Activation marker expression was measured at 24, 48, and 72 hours. MFI, mean fluorescence intensity. Measurements were compared between vehicle and LRAtreatment using an exact Wilcoxon Signed Rank test. * p < 0.05; ** p ≤ 0.016. Figure S8 . HDACis do not induce non-specific cytokine release. PBMC from HIVseropositive participants durably suppressed on cART (n=5) were exposed to vehicle (0.5% DMSO) or HDACis for 3 hours, washed to remove extracellular drug, and maintained in vehicle for the remainder of the culture period. Cytokine concentrations were measured in supernatants collected at 24 hours. Measurements were compared between vehicle and HDACi treatment using an exact Wilcoxon Signed Rank test Figure S9 . Cytokine concentrations in culture supernatants following exposure to LRAs. PBMC from HIV-seropositive participants durably suppressed on cART (n=5-8, depending on sample availability) were exposed to vehicle (0.5% DMSO) or LRAs for (a) 3 or (b) 6 hours, washed to remove extracellular drug, and maintained in vehicle for the remainder of the culture period. Cytokine concentrations were measured in supernatants collected at 24, 48, and 72 hours. Measurements were compared between vehicle and LRA-treatment using an exact Wilcoxon Signed Rank test. * p < 0.05; ** p ≤ 0.016. 
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